Search Results for “cancer” – Page 60 – media

Researchers demonstrate potential of new PET tracer for imaging prostate cancer

In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), for imaging prostate cancer, and set the stage for its possible use in monitoring other cancers.
- Source: news-medical.net
- 535
- August 8, 2017
cancer Company Insight PET prostate tracer
Fast-track pancreatic cancer surgery boosts success, saves money

Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
- Source: pharmatimes
- 405
- August 3, 2017
Clinical Trials NHS pancreatic
UC Riverside tests new biopsy device for cervical cancer

A research team at the University of California, Riverside (UC Riverside) in the US has evaluated a new device manufactured by tissue sampling devices maker Histologics.
- Source: medicaldevices-network.com
- 462
- August 3, 2017
cancer cervical Clinical Trials Researches
AZ, Merck link to develop and commercialise cancer drugs

AstraZeneca and Merck & Co have announced a global strategic oncology collaboration to co-develop and co-commercialise the former’s Lynparza and selumetinib for multiple cancer types.
- Source: pharmatimes
- 488
- July 31, 2017
cancer Lynparza Market Views Researches therapy
NovellusDx to use Gene Editing Institute’s technology for cancer diagnostics

Israel-based NovellusDx has established a genomic cancer research partnership with Christiana Care Health System's Gene Editing Institute to speed-up the development of treatments for the disease.
- Source: Medicaldevice
- 466
- July 24, 2017
cancer Company Insight NovellusDx
Dune Medical’s MarginProbe destined for more than breast cancer, receives $12 million.

Dune Medical, which markets a tool that spots residual breast cancer cells following a lumpectomy, has raised $12.3 million. The funds will drive the development of the company’s technology for other types of cancer.
- Source: fiercebiotech
- 482
- July 10, 2017
breast cancer Market Views Researches
Owlstone’s search into breath biomarkers of cancer

Owlstone Medical and Cancer Research UK (CRUK) have begun a clinical trial designed to identify biomarkers of cancer in breath samples. The goal is to find volatile organic compounds (VOCs) that indicate the presence of cancer, enabling physicians to make quick, noninvasive diagnoses.
- Source: pharmatimes
- 518
- June 15, 2017
cancer Clinical Trials diagnostic therapy
Aspen Pharmacare hit by EU antitrust cancer drug price probe

Aspen Pharmacare is under investigation by the European Commission over its pricing practices for five cancer medicines.
- Source: pharmatimes
- 595
- May 16, 2017
cancer Company Insight EU
the wind rises, accelerates, and accelerates again

The development story of tumor drugs is always so similar: the early stage may be endless suffering, but after countless failures and dashed hopes, once there is a breakthrough, the progress is often unexpected. This is the development of drugs for the treatment of small cell carcinoma (SCLC). SCLC was first discovered about 100 years ago, but it was not until 1968 that the medical community discovered its neuroendocrine origin and finally clearly distinguished it from other lung cancers. In the 1980s, the treatment of platinum-containing chemotherapy combined with chest radiotherapy gradually became clear and became the basic treatment for small cell lung cancer. Although the combination of etoposide and carboplatin/cisplatin (EP) has been the standard treatment for SCLC until now; but we can also clearly see that the battle against small cell lung cancer has entered an accelerated stage. In May of this year, Amgen’s DLL3/CD3 dual antibody Tarlatamab ...
- Source: drugdu
- 27
- November 1, 2024
The third day of the national negotiations! Oncology drugs and traditional Chinese medicines are on display, Pfizer, China Resources Sanjiu, Jianmin, Dizhe…

On October 29, the 2024 national negotiations entered the third day, and a group of companies such as Yangtze River, Yiling, China Resources Sanjiu, Jichuan, and Jianmin took their traditional Chinese medicine varieties to the stage. Before entering the venue in the afternoon, the overall atmosphere on the scene was relatively relaxed. When the staff of the Medical Insurance Bureau called the roll, some company representatives did not respond in time. Other company representatives joked, “Okay, automatically give up,” and everyone laughed. At the scene, many representatives of traditional Chinese medicine companies showed strong confidence in their products, and mentioned the advantages of traditional Chinese medicine over chemical medicine in the treatment of the same disease during the conversation. At the same time, this year’s national negotiations focus on “high-quality, cost-effective innovation” and also apply to traditional Chinese medicine. A representative of a traditional Chinese medicine company with exclusive varieties ...
- Source: drugdu
- 30
- October 31, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.